Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell...查看全文
Replix锐璞美股03-21 09:18
$Prime Medicine(PRME)$ 2024年Q4, $Beam Therapeutics(BEAM)$ 要公布BEAM-101和BEAM-201在SCD和T-ALL/T-LL的临床结果,如果结果好的话,PRME也会跟着上涨,毕竟技术同宗同源,相互印证;同时6月份CGD IND。这三个都是弱催化剂,更重要是降息!一旦降息,这些被利率粉碎的顶流创新公司将重新大展拳...查看全文
医药指数大家族02-28 10:52
$纳指生物科技ETF(SH513290)$ 溢价再度走高,在隔夜标的指数(NBI)大涨提振下,一度涨近2%,溢价率再度冲高。
成份股$Beam Therapeutics(BEAM)$ 狂涨25%,疫苗巨头莫德纳(Moderna)涨超2%,再生元制药、吉利德科学、阿斯利康、渤健均收涨。
上交所权威数据显示,纳指生物科技ETF(513290...查看全文
美股滚雪球02-28 10:56
$Beam Therapeutics(BEAM)$ 靠合作实现净利润净利润1.428亿美元,而2022年第四季度净亏损3830万美元。
公司财报超出华尔街预期,收入的增长主要反映了Beam公司与礼来公司(Eli Lilly)在10月份签署的一项协议,根据该协议,制药巨头礼来公司同意购买Beam公司与Verve Therapeutics公司(VERV Thera...查看全文
Beam Therapeutics(BEAM)02-01 05:55
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-000541 Act: 33 Size: 4 KB 网页链接查看全文
Beam Therapeutics(BEAM)04-03 04:25
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-002884 Act: 33 Size: 5 KB 网页链接查看全文
Beam Therapeutics(BEAM)04-03 04:15
$Beam Therapeutics(BEAM)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040150 Size: 4 KB 网页链接查看全文
Beam Therapeutics(BEAM)04-05 09:05
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0000950170-24-042028 Act: 33 Size: 5 KB 网页链接查看全文
Replix锐璞美股03-26 21:08
$Beam Therapeutics(BEAM)$ Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
$美国生科ETF-SPDR(XBI)$ $Viking Therapeutics(VKTX)$查看全文
Replix锐璞美股03-21 09:18
$Prime Medicine(PRME)$ 2024年Q4, $Beam Therapeutics(BEAM)$ 要公布BEAM-101和BEAM-201在SCD和T-ALL/T-LL的临床结果,如果结果好的话,PRME也会跟着上涨,毕竟技术同宗同源,相互印证;同时6月份CGD IND。这三个都是弱催化剂,更重要是降息!一旦降息,这些被利率粉碎的顶流创新公司将重新大展拳...查看全文
美股滚雪球02-28 10:56
$Beam Therapeutics(BEAM)$ 靠合作实现净利润净利润1.428亿美元,而2022年第四季度净亏损3830万美元。
公司财报超出华尔街预期,收入的增长主要反映了Beam公司与礼来公司(Eli Lilly)在10月份签署的一项协议,根据该协议,制药巨头礼来公司同意购买Beam公司与Verve Therapeutics公司(VERV Thera...查看全文
医药指数大家族02-28 10:52
$纳指生物科技ETF(SH513290)$ 溢价再度走高,在隔夜标的指数(NBI)大涨提振下,一度涨近2%,溢价率再度冲高。
成份股$Beam Therapeutics(BEAM)$ 狂涨25%,疫苗巨头莫德纳(Moderna)涨超2%,再生元制药、吉利德科学、阿斯利康、渤健均收涨。
上交所权威数据显示,纳指生物科技ETF(513290...查看全文
Replix锐璞美股02-27 19:46
$Beam Therapeutics(BEAM)$ 新鲜的财报出炉了
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell...查看全文
Replix锐璞美股2023-11-13 10:19
$Verve Therapeutics(VERV)$ 第一个人体base editing数据新鲜出炉:随着剂量的升高,ALT也升高,令人担心。
In the interim dataset, six patients were treated at sub-therapeutic doses (0.1 mg/kg and 0.3 mg/kg) and three patients were treated at potentially therapeutic doses (0.45...查看全文
辉瑞与Beam Therapeutics达成独家多目标研究合作,推进针对一系列罕见疾病的新型体内碱基编辑计划。 网页链接
$Beam Therapeutics(BEAM)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-046028 Act: 34 Size: 2 MB 网页链接
$Beam Therapeutics(BEAM)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-046017 Act: 34 Size: 4 MB 网页链接
$Beam Therapeutics(BEAM)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-046022 Act: 34 Size: 1 MB 网页链接
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0000950170-24-042028 Act: 33 Size: 5 KB 网页链接
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0000950170-24-042027 Act: 33 Size: 4 KB 网页链接
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0000950170-24-042026 Act: 33 Size: 4 KB 网页链接
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0000950170-24-042025 Act: 33 Size: 5 KB 网页链接
$Beam Therapeutics(BEAM)$ 144 Report of proposed sale of securities Accession Number: 0000950170-24-042024 Act: 33 Size: 5 KB 网页链接
$Beam Therapeutics(BEAM)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-041432 Size: 11 KB 网页链接
$Beam Therapeutics(BEAM)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-041437 Size: 5 KB 网页链接